Organic compound salts

1. A hydrobromide salt of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in crystalline form, comprising peaks in an x-ray powder diffraction (XRPD) diffractogram at 2θ values of 14.5°±0.2°, 16.7°±0.2°, 20.7°±0.2°, 24.2°±0.2°, 24.8°±0.2° and 27.4°±0.2° as measured using an x-ray wavelength of 1.5406 Å.

2. A hydrobromide salt of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in crystalline form, comprising peaks in an x-ray powder diffraction (XRPD) diffractogram at 2θ values of 14.5°±0.2 20 , 21.4°±0.2° and 24.2°±0.2° as measured using an x-ray wavelength of 1.5406 Å.

3. A hydrobromide salt of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in crystalline form, comprising peaks in an x-ray powder diffraction (XRPD) diffractogram at 2θ values of 18.7°±0.2°,19.6°±0.2° and 24.7°±0.2° as measured using an x-ray wavelength of 1.5406 Å.

4. The salt of claim 2 , comprising peaks in an x-ray powder diffraction (XRPD) diffractogram at 20 values of 14.5°±0.2°, 20.7°+0.2°, 21.4°±0.2°, 24.2°±0.2°, and 25.3°±0.2° as measured using an x-ray wavelength of 1.5406 Å.

5. A pharmaceutical composition comprising the salt of claim 1 .

6. A pharmaceutical composition comprising the salt of claim 2 .

7. A pharmaceutical composition comprising the salt of claim 3 .

8. A pharmaceutical composition comprising the salt of claim 4 .

9. A hydrobromide salt of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in crystalline form, comprising peaks in an x-ray powder diffraction (XRPD) diffractogram at 2θ values of 14.5°±0.2°, 17.0°±0.2° and 24.2°±0.2° as measured using an x-ray wavelength of 1.5406 Å.

10. The salt of claim 9 , comprising peaks in an x-ray powder diffraction (XRPD) diffractogram at 20 values of 14.5°±0.2°, 16.7°+0.2°, 17.0°±0.2°, 20.7°±0.2°, 24.2°±0.2°, 24.8°±0.2°, and 27.4°±0.2° as measured using an x-ray wavelength of 1.5406 Å.

11. A hydrobromide salt of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in crystalline form, comprising peaks in an x-ray powder diffraction (XRPD) diffractogram at 2 θ values of 14.5°±0.2°, 17.0°±0.2 20 , 20.6°±0.2°, 20.7°±0.2° and 24.2°±0.2 as measured using an x-ray wavelength of 1.5406 Å.

12. The salt of claim 3 , comprising peaks in an x-ray powder diffraction (XRPD) diffractogram at 20 values of 13.8°±0.2°, 14.5°±0.2°, and 23.4°±0.2° as measured using an x-ray wavelength of 1.5406 Å.

13. The salt of claim 3 , comprising peaks in an x-ray powder diffraction (XRPD) diffractogram at 20 values of 13.8°±0.2°, 14.5°±0.2°, 23.4°±0.2°, 27.3°±0.2°, and 24.9°±0.2° as measured using an x-ray wavelength of 1.5406 Å.

14. A pharmaceutical composition comprising the salt of claim 9 .

15. A pharmaceutical composition comprising the salt of claim 10 .

16. A pharmaceutical composition comprising the salt of claim 11 .

17. A pharmaceutical composition comprising the salt of claim 12 .

18. A pharmaceutical composition comprising the salt of claim 13 .

19. A hydrobromide salt of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in crystalline form, comprising peaks in an x-ray powder diffraction (XRPD) diffractogram at 2θ values of 14.5°, 16.7°, 20.7°, 24.2°, 24.8° and 27.4° as measured using an x-ray wavelength of 1.5406 Å.

20. A hydrobromide salt of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in crystalline form, comprising peaks in an x-ray powder diffraction (XRPD) diffractogram at 2θ values of 14.5°, 21.6° and 24.2° as measured using an x-ray wavelength of 1.5406 Å.

21. A hydrobromide salt of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in crystalline form, comprising peaks in an x-ray powder diffraction (XRPD) diffractogram at 2θ values of 18.7°, 19.6° and 24.7° as measured using an x-ray wavelength of 1.5406 Å.

22. The salt of claim 20 , comprising peaks in an x-ray powder diffraction (XRPD) diffractogram at 2θ values of 14.5°, 20.7°, 21.6°, 24.2° and 25.3° as measured using an x-ray wavelength of 1.5406 Å.